Fly News Breaks for January 13, 2020
Jan 13, 2020 | 11:20 EDT
Piper Sandler analyst Matt O'Brien views NuVasive's preliminary Q4 results as "strong." Given the performance and "improving dynamics" in the spine market, he remains confident that NuVasive can outperform once again in 2020. As such, he reiterates an Overweight rating on the name with a $90 price target.
News For NUVA From the Last 2 Days
There are no results for your query NUVA